Worth reading
93Important
Scored from 1 of 6 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Contents of this document
Summary of Q&A4 items taken from the company’s own explanation
What the company explained in this material
Key points of the Q&AKey questions raised by investors at the briefing and the company's answers
- Legality of the points program under the Ministry of Health, Labour and Welfare administrative notice and its impact on business performance
- Inquiries concerning the Ministry of Health, Labour and Welfare administrative notice and plans for additional disclosure
- Actual sales from the Everyone's Medicine Cabinet business versus plan
- Promising businesses among the business purposes added through the articles of incorporation amendment
- Disputes with contracted pharmacies and their incidence rate
- Response to discrepancies in contractual terms
- Future dividend policy
New initiatives
- End of the questionnaire and points program related to prescription reservations
- Consideration of a pre-illness prevention business
- Investment in software, AI, new service development and M&A
Key KPIsA metric the company considers important as a management benchmark.
- Number of inquiries concerning the Ministry of Health, Labour and Welfare administrative noticeApproximately 40
Payout ratio
15 %
| Item | Details |
|---|---|
| Document type | Summary of Q&A |
| Key KPIs | Indicator name Number of inquiries concerning the Ministry of Health, Labour and Welfare administrative notice / Value Approximately 40 / Year on year against the same period last year Not disclosed |
| Payout ratio | 15 % |
| Key points of the Q&A | Legality of the points program under the Ministry of Health, Labour and Welfare administrative notice and its impact on business performance, Inquiries concerning the Ministry of Health, Labour and Welfare administrative notice and plans for additional disclosure, Actual sales from the Everyone's Medicine Cabinet business versus plan, Promising businesses among the business purposes added through the articles of incorporation amendment, Disputes with contracted pharmacies and their incidence rate, Response to discrepancies in contractual terms, Future dividend policy |
| New initiatives | End of the questionnaire and points program related to prescription reservations, Consideration of a pre-illness prevention business, Investment in software, AI, new service development and M&A |
Items this document does not state (26)
Fiscal Period CoveredNet SalesOperating profitOrdinary incomeNet incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / Share
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The questionnaire and points program related to prescription reservations were ended because they could potentially cause inconvenience to pharmacies and users. The company explained that the check-in and record-entry points were not related to directing users to specific pharmacies and were not covered by the issues addressed in the administrative notice, so they would have no impact on business performance. It also stated that it was encouraged by the potential of its pre-illness prevention business, but did not disclose specific details. The company considers the current 15% payout ratio appropriate because it is in a growth phase requiring investment in software, AI, new service development and M&A.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.